RE:RE:RE:RE:RE:Peak Sales of MCNA and potential. BELLEVILLE, ON, Nov. 15, 2011 - Bioniche Life Sciences Inc. (TSX: BNC) (ASX: BNC), a research-based, technology-driven Canadian biopharmaceutical company, offers its sincere congratulations to Dr. Alvaro Morales who became a Member of the Order of Canada earlier this month in recognition of his contributions to advancing the field of urology, notably in the areas of oncology and sexual dysfunction.
Dr. Morales was the Principal Investigator in the Phase I and II clinical trials, as well as the first Phase III clinical trial with the Company's Mycobacterial Cell Wall-DNA Complex (MCC) - trademarked Urocidin™ - in the treatment of bladder cancer. He has been an enthusiastic supporter of this technology, believing that it could have fewer side effects, better tolerability, and be safer for physicians to handle than the current standard bladder cancer therapy, bacillus Calmette-Guérin (BCG).
During the 1970s while working in the Department of Urology at Queen's University in Kingston, Ontario, Canada , Dr. Morales hypothesized that infecting the bladder with BCG would provoke an immune system response that would be sufficiently robust to eliminate some bladder tumours. BCG is a live vaccine developed in the 1920s to prevent Tuberculosis in humans. Dr. Morales ' pioneering work formed the basis for registration of BCG as a bladder cancer therapy. Since that registration, he has been anticipating a new generation of therapy.
"We are proud to have had Dr. Morales as a colleague and friend of our Company for more than 25 years," said Mr. Graeme McRae , Chairman, President & CEO of Bioniche Life Sciences Inc. "The Member of the Order of Canada recognizes his lifetime of distinguished service to the field of urology and his unwavering commitment to finding efficacious therapies for bladder cancer patients."
Wussy